| Citation | David Lodge is noted for major advances in the field of glutamate receptor pharmacology and physiology. He contributed significantly to characterizing ionotropic receptors into NMDA, AMPA and kainate classes and more latterly to characterizing metabotropic glutamate receptors. Lodge followed this through by defining their roles in synaptic transmission and plasticity and elucidating their potential as therapeutic targets. His seminal discovery of the NMDA antagonist action of ketamine, phencyclidine and similar psychotomimetics revolutionised academic and industrial research into therapeutics for schizophrenia research, and latterly to depression. Lodge has helped drive compounds to the clinic for schizophrenia, Alzheimer’s and epilepsy. |